This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or refuse these technologies

AP39, a novel mitochondria-targeted H2S donor, was designed and synthesized by Medicilon

2023-07-17

Page View：

Alzheimer's disease (AD) is the most universal age-related neurodegenerative disease. AP39 is a newly synthesized mitochondrially targeted H₂S donor on mitochondrial function. AP39 increases intracellular H₂S levels, mainly in mitochondrial regions. AP39 exerts dose-dependent effects on mitochondrial activity in APP/PS1 neurons. AP39, a novel mitochondria-targeted H₂S donor, was designed and synthesized by Medicilon.

Reference:

Feng-Li Zhao, et al. AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and Neurons. Oxid Med Cell Longev. 2016;2016:8360738. doi: 10.1155/2016/8360738.

Mitochondria Hydrogen-Sulfide-Donor Alzheimer's-Disease Neuron

Return

Relevant News

zapERtrap: A light-regulated ER release system reveals unexpected neuronal trafficking pathways. Synthesis of zapalog was performed by Medicilon

2023-07-11

zapERtrap opens the door to previously unapproachable questions concerning how proteins are processed, trafficked, and secreted in space and time in complex cellular environments. zapERtrap relies on a small-molecule protein dimerizer zapalog, which consists of the antibiotic trimethoprim tethered to a synthetic ligand of FK506-binding protein through a photocleavable linker. Synthesis of Zapalog was performed by Medicilon.

TR-107 is a potent chemical activator of the human mitochondrial protease ClpP. Pharmacokinetic analysis were evaluated by Medicilon

2023-07-11

Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype. ClpP is a component of the ClpXP protein complex localized in the mitochondrial matrix. Modifiers of ClpP activity have demonstrated anti-cancer properties. TR-107 is a potent chemical activator of the human mitochondrial protease ClpP, with excellent potency, specificity and drug-like properties. TR‐107 shows ClpP‐dependent growth inhibition in the low nanomolar range that is equipotent to Paclitaxel in TNBC cell models. The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.